Racial Disparities Seen Among Hospitalized Patients With Decompensated Cirrhosis
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 26, 2023 -- Among individuals hospitalized with decompensated cirrhosis, racial and ethnic disparities in the use of complex life-saving procedures and mortality persist, according to a study published online July 20 in JAMA Network Open.
Lauren D. Nephew, M.D., from Indiana University School of Medicine in Indianapolis, and colleagues evaluated the associations of race and ethnicity with the likelihood of receiving procedures to treat decompensated cirrhosis over time in the United States. The analysis included data on 717,580 cirrhosis admissions among patients with portal hypertension-related complications identified from the National Inpatient Sample during 2009 to 2018.
The researchers observed no significant differences by race or ethnicity in the odds of receiving upper endoscopy for variceal hemorrhage. However, Black patients had lower odds of undergoing transjugular portosystemic shunt for variceal hemorrhage (odds ratio, 0.54) and ascites (odds ratio, 0.34) than White patients. During the study period, the disparity in receipt of liver transplant improved for Black and Hispanic patients; however, by 2018, both groups had lower odds than White patients (odds ratios, 0.66 and 0.74 for Black and Hispanic patients, respectively). Similarly, during the study period, the odds of death in Black and Hispanic patients declined; however, the odds of death remained higher in Black patients versus White patients in 2018 (odds ratio, 1.08).
"These findings suggest that racial and ethnic disparities in receipt of complex life-saving procedures and in mortality in the United States persisted over time," the authors write. "Targeted efforts will be required to ensure that another decade does not pass without improved equity in these lifesaving procedures."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.